Key features and details
- Selective Panx1 hemichannel inhibitor
- CAS Number: 7421-40-1
- Purity: > 98%
- Soluble in water to 100 mM
- Form / State: Solid
- Source: Synthetic
Product nameCarbenoxolone disodium salt, Panx1 hemichannel inhibitor
DescriptionSelective Panx1 hemichannel inhibitor
Biological descriptionSelective Panx1 hemichannel inhibitor. HSP inducer. Reduces COX-2, iNOS, and NF-κB expression. Reduces oxidative stress and shows anti-inflammatory effects in vivo. Orally active.
Chemical name(2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-(3-carboxylatopropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylate disodium salt
Storage instructionsStore at Room Temperature. The product can be stored for up to 12 months.
Solubility overviewSoluble in water to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab143590 has been referenced in 3 publications.
- Schinner C et al. Stabilization of desmoglein-2 binding rescues arrhythmia in arrhythmogenic cardiomyopathy. JCI Insight 5:N/A (2020). PubMed: 32376797
- Yin X et al. Roles of astrocytic connexin-43, hemichannels, and gap junctions in oxygen-glucose deprivation/reperfusion injury induced neuroinflammation and the possible regulatory mechanisms of salvianolic acid B and carbenoxolone. J Neuroinflammation 15:97 (2018). PubMed: 29587860
- Schultz ML et al. Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo. Neurobiol Dis 115:182-193 (2018). PubMed: 29660499